Results 31 to 40 of about 1,327 (120)

Ablative radiotherapy in castration‐resistant prostate cancer

BJU International, Volume 138, Issue 4, Page 659-665, October 2026.
Objective To prove the oncological benefit of ablative radiotherapy in patients with up to five metastases from castration‐resistant prostate cancer (CRPC) a single‐centre randomised trial was initiated. Patients and Methods This monocentric, randomised, phase II clinical trial enrolled patients with up to five prostate‐specific membrane antigen ...
Tobias Hölscher, Fabian Lohaus, Lydia Koi, Jörg Kotzerke, Sebastian Hoberück, Christian Thomas, Angelika Borkowetz, Steffen Löck, Mechthild Krause, Esther G.C. Troost   +9 more
wiley   +1 more source

Rechallenge With Immunotherapy for ES‐SCLC: Efficacy and Safety From a Retrospective Propensity Score‐Matched Study

Cancer Medicine, Volume 15, Issue 9, September 2026.
ABSTRACT Background Although immunotherapy combined with platinum‐based chemotherapy is now the standard first‐line treatment for extensive‐stage small cell lung cancer (ES‐SCLC), the benefit of continuing immune checkpoint inhibitors (ICIs) after disease progression (PD) remains uncertain.
Yuxia Wang, Yunfeng Tong, Yang Pan, Xinyue Li, Hui Li   +4 more
wiley   +1 more source

Patterns of Progression in Metastatic Estrogen Receptor Positive Breast Cancer: An Argument for Local Therapy

International Journal of Breast Cancer, 2017
Purpose. Despite advances in endocrine therapy (ET), metastatic estrogen receptor positive breast cancer (BrCA) remains incurable. Though the mechanisms of resistance to ET have been studied extensively, the anatomic pattern of disease progression ...
Patrick Kelly, Zhe Ma, Said Baidas, Rebecca Moroose, Nikita Shah, Roi Dagan, Eleftherios Mamounas, Justin Rineer   +7 more
doaj   +1 more source

Checkpoint inhibitors in non-small cell lung carcinoma therapy for progression to the brain (clinical observation)

Медицинский совет, 2022
The development of a new area of antitumor drug therapy, immunotherapy using immune checkpoint inhibitors targeting PD-1/PD-L1, has significantly changed approaches to the treatment of advanced non-small cell lung cancer (NSCLC).
L. Yu. Vladimirova, I. L. Popova, N. A. Abramova, M. A. Teplyakova, N. M. Tikhanovskaya, A. A. Lianova, A. E. Storozhakova, L. A. Ryadinskaya, S. N. Kabanov, E. A. Kalabanova   +9 more
doaj   +1 more source

Remarkable Response to Immune Checkpoint Inhibition After Early Aggressive Recurrence Following Robot‐Assisted Radical Cystectomy for Bladder Squamous Cell Carcinoma: A Case Report

IJU Case Reports, Volume 9, Issue 5, September 2026.
ABSTRACT Introduction Squamous cell carcinoma is a rare bladder cancer subtype with poor prognosis in advanced stages. Currently, there is no established systemic therapy, including immune checkpoint inhibitors, for this subtype. Case Presentation A 49‐year‐old man with pure bladder squamous cell carcinoma arising from a diverticulum with pelvic lymph ...
Kazuma Soya, Takeru Fujimoto, Yu Osaki, Koji Matsumoto, Yusuke Takei, Yoshio Sugino, Tsutomu Maruta, Hiroshi Iwamura   +7 more
wiley   +1 more source

Stereotactic body radiotherapy for oligoprogression with or without switch of systemic therapy

Clinical and Translational Radiation Oncology
Background: Oligoprogression is defined as cancer progression of a limited number of metastases under active systemic therapy. The role of metastasis-directed therapy, using stereotactic body radiotherapy (SBRT), is controversial as is the continuation ...
Jonas Willmann, Eugenia Vlaskou Badra, Selma Adilovic, Maiwand Ahmadsei, Sebastian M. Christ, Stephanie Tanadini-Lang, Michael Mayinger, Matthias Guckenberger, Nicolaus Andratschke   +8 more
doaj   +1 more source

The Role of Stereotactic Radiotherapy in the Management of Melanoma, A Retrospective Single Institute Preliminary Study of 30 Patients

Pathology and Oncology Research, 2022
Cutaneous melanoma is the third most common type of skin cancer in the world. The incidence of melanoma is increasing in most countries, however, mortality seems to be slowly decreasing.
Mihály Kispál, Levente Zsolt Jánváry, Tímea Balatoni, Stelczer Gábor, Imre Fedorcsák, Bőcs Katalin, István Kenessey, Gabriella Liszkay   +7 more
doaj   +1 more source

Radioiodine‐Refractory Differentiated Thyroid Cancer: Definition, Molecular Mechanisms, and Advances in Precision Therapy

Cancer Innovation, Volume 5, Issue 4, August 2026.
Radioiodine‐refractory differentiated thyroid cancer (RAIR‐DTC) management now spans selective kinase inhibitors, MAPK‐pathway redifferentiation, VEGFR multikinase TKIs, and biomarker‐driven immunotherapy. We propose a three‐axis decision framework integrating molecular driver, evidence level, and patient dimension to guide individualized treatment ...
Yamin Li, Zuoxiang He
wiley   +1 more source

Prognostic Factors and Optimal Response Interval for Stereotactic Body Radiotherapy in Patients With Lung Oligometastases or Oligoprogression From Colorectal Cancer

Frontiers in Oncology, 2019
Purpose: To analyze the prognostic factors and optimal response interval for stereotactic body radiotherapy (SBRT) in patients with lung oligometastases (OM) or oligoprogression (OP) from colorectal cancer (CRC).Method: Patients with lung OM or OP from ...
Shuai Li, Dezuo Dong, Jianhao Geng, Xianggao Zhu, Chen Shi, Yangzi Zhang, Hongzhi Wang, Shun Zhou, Hao Wu, Yong Cai, Yongheng Li, Weihu Wang   +11 more
doaj   +1 more source

Time to Next Treatment Following Sub-Ablative Progression Directed Radiation Therapy for Oligoprogressive Non-Small-Cell Lung Cancer

Current Oncology
We aimed to evaluate whether progression-directed radiation therapy (PDRT) can prolong the initiation of a subsequent systemic therapy regimen in a cohort of patients with oligoprogressive NSCLC.
Riccardo Ray Colciago, Chiara Chissotti, Federica Ferrario, Maria Belmonte, Giorgio Purrello, Valeria Faccenda, Denis Panizza, Stefania Canova, Gaia Passarella, Diego Luigi Cortinovis, Stefano Arcangeli   +10 more
doaj   +1 more source